Niloff J M, Knapp R C, Jones G, Schaetzl E M, Bast R C
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):895-6.
Recombinant leukocyte alpha interferon (rIFN-alpha A; Hoffmann-La Roche, Inc) was administered to 15 patients with recurrent or persistent ovarian carcinoma. All patients had been previously treated with surgery and combination chemotherapy including cyclophosphamide (15 patients), doxorubicin (14), and cisplatin (14). Three patient had also previously undergone radiation therapy. At the start of therapy the largest tumor size was less than or equal to 2 cm in four patients and greater than 2 cm in 11. Interferon was administered in three times weekly for 8 weeks at a dose of 20 X 10(6) units/m2, with average drug levels of 2267 pg/ml 6 hours after im injection. In three patients (20%), the dose had to be reduced by 50% because of drug toxicity. Side effects included fever (greater than 101 degrees F) in 12 patients, fatigue in ten, headache in two, diarrhea in two, and reversible myelosuppression in five. Of the 15 patients, one had mixed response lasting 12 weeks, two had stable disease of 8 weeks' duration, and 12 had disease progression.
重组白细胞α干扰素（rIFN-αA；霍夫曼-罗氏公司）应用于15例复发性或持续性卵巢癌患者。所有患者此前均接受过手术及联合化疗，其中包括环磷酰胺（15例）、阿霉素（14例）和顺铂（14例）。3例患者此前还接受过放射治疗。治疗开始时，4例患者最大肿瘤直径小于或等于2 cm，11例患者大于2 cm。干扰素每周给药3次，共8周，剂量为20×10⁶单位/平方米，皮下注射后6小时平均药物水平为2267 pg/ml。3例患者（20%）因药物毒性不得不将剂量减少50%。副作用包括12例患者发热（体温高于101华氏度）、10例疲劳、2例头痛、2例腹泻以及5例可逆性骨髓抑制。15例患者中，1例有持续12周的混合反应，2例病情稳定达8周，12例病情进展。
